Law360, New York (July 30, 2012, 9:03 PM ET) -- The European Commission brought its second pay-for-delay case on Monday challenging patent settlements between Servier SAS and several generic-drug makers, and attorneys say the European Union watchdog may have an easier time barring the practice than its U.S. counterpart because the bloc's courts rarely overrule the regulator on the scope of EU competition law.
The regulator lodged a two-pronged statement of objections against Servier and several generics makers, accusing the French drugmaker of buying up limited technologies used to produce perindopril, a cardiovascular treatment sold as...
EU Provides Favorable Turf For Pay-For-Delay Cases
To view the full article, take a free trial now.
